Department of Internal Medicine, Division of Gastroenterology, Hepatology and Nutrition, The University of Texas Health Science Center, Houston, TX.
J Clin Gastroenterol. 2021 Aug 1;55(7):e56-e65. doi: 10.1097/MCG.0000000000001453.
Endoscopic gastrointestinal anastomosis using lumen-apposing metal stents (EGAL) is a new technique that is used as an alternative method to bypass benign or malignant strictures. Endoscopists take advantage of 2 bowel loops that are close to each other and place a stent between the lumen of these 2 bowel loops. The authors performed this systematic review and meta-analysis to evaluate the efficacy and safety of this rising procedure.
Electronic database searches were conducted for full eligible articles that were published from the inception to July 2019 using the EGAL procedure to bypass malignant or benign obstruction or to restore bowel integrity after a gastrointestinal altering surgery. The primary outcome of this meta-analysis was to assess efficacy through technical and clinical success. Secondary outcomes were to assess safety through adverse events and to assess the rate of stent maldeployment and the rate of reintervention during the study period.
Eight studies were eligible, providing data on 269 patients who underwent 271 EGAL procedures. The median age was 65 years (interquartile range: 63 to 66) with 46% male individuals. Out of 269 patients, 203 underwent EGALs because of malignant etiology and 66 underwent EGAL for benign etiology. The median duration of follow-up was 114 days (interquartile range: 78 to 121). Technical success rate was 94.1% [95% confidence interval (CI), 91.4%-96.9%]. Clinical success rate was 91.4% (95% CI, 88.1%-94.7%). Adverse events rate was 8.5% (95% CI, 4.7%-12.3%). Stent maldeployment rate was 9.5% (95% CI, 3.5%-15.4%) of the total performed EGALs and the reintervention rate was 6.0% (95% CI, 2.3%-9.8%).
EGAL procedure has high efficacy and a relatively safe profile and it can be performed in selected patients. Comparison between EGAL and other conventional therapies is difficult because of the lack of randomized trials.
内镜下胃肠吻合术(EGAL)使用的腔内置入吻合金属支架是一种新的技术,可作为治疗良性或恶性狭窄的替代方法。内镜医生利用两个彼此靠近的肠袢,在这两个肠袢的腔内置入支架。作者进行了这项系统评价和荟萃分析,以评估该新兴技术的疗效和安全性。
对从成立到 2019 年 7 月发表的使用 EGAL 术式治疗恶性或良性梗阻或修复胃肠手术后肠完整性的所有合格文章进行电子数据库检索。该荟萃分析的主要结局是通过技术和临床成功率评估疗效。次要结局是通过不良事件评估安全性,并评估研究期间支架移位和再介入的发生率。
8 项研究符合条件,提供了 269 名接受 271 例 EGAL 手术患者的数据。患者的中位年龄为 65 岁(四分位距:63 至 66 岁),男性占 46%。269 名患者中,203 名因恶性病因接受 EGAL,66 名因良性病因接受 EGAL。中位随访时间为 114 天(四分位距:78 至 121 天)。技术成功率为 94.1%(95%置信区间:91.4%至 96.9%)。临床成功率为 91.4%(95%置信区间:88.1%至 94.7%)。不良事件发生率为 8.5%(95%置信区间:4.7%至 12.3%)。支架移位率为 9.5%(95%置信区间:3.5%至 15.4%),再介入率为 6.0%(95%置信区间:2.3%至 9.8%)。
EGAL 术具有较高的疗效和相对安全的特点,可在选定的患者中进行。由于缺乏随机试验,EGAL 与其他常规治疗方法的比较比较困难。